Close Menu

NEW YORK – Swift Biosciences announced on Monday it will exclusively distribute BillionToOne's test kit for detecting SARS-CoV-2. 

The qSanger-COVID-19 assay, which received Emergency Use Authorization from the US Food and Drug Administration earlier this month, detects SARS-CoV-2 in samples from nasal, nasopharyngeal, and oropharyngeal swabs and has a testing capacity of 1 million tests per day, according to Swift Biosciences. 

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Kaiser Health News reports San Francisco and Alameda counties in California are no longer using Verily Life Sciences' COVID-19 testing program.

The New York Times reports that developers in New York City are increasingly interested in life science spaces.

A UK study has found that antibodies against SARS-CoV-2 may decline over time, Reuters reports.

In PNAS this week: genetic and epigenetic variation in individuals with diabetic kidney disease, spontaneous genetic alterations in Saccharomyces cerevisiae, and more.